Achievement of the ESC recommendations for secondary prevention of cardiovascular risk factors in high-risk patients with type 2 diabetes: A real-world national cohort analysis

Salem, Ahmed M. H.; Harris, Daniel; Bray, Jonathan J.H.; Obaid, Daniel R.; Stephens, Jeffrey W.; Halcox, Julian PJ

doi:10.1016/j.ijcard.2023.02.004

Record: found
Abstract: not found
Article: not found

Achievement of the ESC recommendations for secondary prevention of cardiovascular risk factors in high-risk patients with type 2 diabetes: A real-world national cohort analysis

Author(s): Ahmed M. Salem , Daniel Harris , Jonathan J.H. Bray , Daniel R. Obaid , Jeffrey W. Stephens , Julian Halcox

Publication date Created: April 2023

Publication date (Print): April 2023

Journal: International Journal of Cardiology

Publisher: Elsevier BV

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" id="d12006199e117">To assess compliance with European Society of Cardiology (ESC) secondary prevention recommendations in a nationwide contemporary population with diabetes mellitus (DM) and coronary artery disease. </p>

Related collections

Most cited references 42

Record: found
Abstract: found
Article: not found

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Bernard Zinman, Christoph Wanner, John M. Lachin … (2015)

The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.

0 comments Cited 2503 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: not found
Article: not found

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

François Mach, Colin Baigent, Alberico L. Catapano … (2020)

0 comments Cited 2155 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen Wiviott, Itamar Raz, Marc Bonaca … (2018)

The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.